Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study
SERENA-3 demonstrates that camizestrant 75 mg once daily (Phase III dose) is well-tolerated and achieves maximal reduction in ER through known mechanisms, that is, antagonism and degradation, by 5-7 days, and proliferation suppression determined by Ki67 expression, by 12-15 days. These data support camizestrant 75 mg once daily as the preferred dose for ongoing clinical development and highlight the importance of presurgical WOO studies in guiding dose selection.
Authors
- Myria Nikolaou
- Ekaterine Arkania
- Andy Sykes (ORCID: https://orcid.org/0000-0003-2257-4841)
- Cheung KL
- Alastair Mathewson
- Teresa Klinowska (ORCID: https://orcid.org/0000-0003-1997-7340)
- Iain Moppett (ORCID: https://orcid.org/0000-0003-3750-6067)
- Christopher J. Morrow (ORCID: https://orcid.org/0000-0003-1524-9426)
- Justin P.O. Lindemann (ORCID: https://orcid.org/0000-0003-1531-9754)
- Zaza Katashvili
- Teimuraz Gogitidze
- Gia Nemsadze
- Giorgi Dzagnidze
- Maxine Ajimi
- Juan Enrique Bargalló Rocha
- John F.R. Robertson
- Maurizio Scaltriti
Institutions
- Batumi Shota Rustaveli State University (GE)
- University of Nottingham (GB)
- Royal Derby Hospital (GB)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Poland) (PL)
- David Tvildiani Medical University (GE)
- AstraZeneca (Spain) (ES)
- Instituto Nacional de Cancerología (MX)
- Batumi Independent University (GE)
- Tbilisi State Medical University (GE)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1200/jco-25-01548
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00